TAUNS Laboratories, Inc.
Connect Afya Ltd.
Announcement of the Strategic Capital and Business Alliance
between TAUNS Laboratories, Inc. and Connect Afya Ltd.
IZUNOKUNI, Japan, August 2, 2024 - TAUNS Laboratories, Inc. (Headquarters: Izunokuni-shi, Shizuoka,
Japan; President and CEO: Masaki Nonaka), hereinafter referred to as TAUNS, and Connect Afya Ltd.
(Headquarters: Tatsuno-shi, Hyogo, Japan; Founder and CEO: Yoichi Shimada), hereinafter referred to asConnect Afya, announce that TAUNS has subscribed to a third-party allotment of new shares by Connect
Afya, and that they have entered into a basic agreement on business alliance for the development of new
IVD products and the expansion of international sales (Africa).
As one of the largest Japanese in vitro diagnostics companies, TAUNS manufactures and sells in vitro
diagnostic products based on various diagnostic technologies in Japan and abroad. TAUNS was listed on
the Tokyo Stock Exchange Standard Market (Securities Code: 197A) on June 20, 2024.
The aim of this strategic capital and business alliance is to establish a foothold for the development ofproduct supply systems and the promotion of joint research and other activities in the African region withConnect Afya, which aims to realize a society in which the average life expectancy of the people of Africa ison par with that of developed countries, despite the regionʼs fragile infrastructure and serious medical issues.
We believe that the alliance with Connect Afya will help us advance our eﬀorts to realize our corporate
slogan, “Peace of mind through diagnostic technology.”
Masaki Nonaka, President and CEO of TAUNS, and Yoichi Shimada, Founder and CEO of Connect Afya,commented on the alliance as follows.
Comment from Masaki Nonaka, President and CEO of TAUNSWe are very pleased with this partnership with Connect Afya, a Japanese company that is committed tosolving healthcare issues in Africa. We look forward to working together with Connect Afya to help thepeople in the region with our diagnostic technology.
Comment from Yoichi Shimada, Founder and CEO of Connect Afya
Kenya and other parts of Africa are overwhelmingly lacking in medical infrastructure.
Through this capital and business alliance, we will accelerate our mission of “bringing necessary medicalcare to where it is needed” and will make further eﬀorts to ensure that TAUNS' superior diagnostictechnology is used by the people of Africa.

About TAUNS:Founded in 1987 in Numazu City, Shizuoka, Japan, TAUNS is an R&D-oriented manufacturer withstrengths in diagnostic technology. TAUNS' corporate slogan is “Peace of mind through diagnostic
technology." TAUNS has been providing antigen test kits to the world, mainly in the ﬁeld of respiratory
infectious diseases, utilizing its long-standing know-how. In recent years, through capital and businessalliances with several bio-ventures, we have been working to solve problems in the ﬁelds of prevention, predisease, and chronic disease diagnosis. For more information, please visit https://www.tauns.co.jp/en/.
About Connect Afya:Connect Afya is a startup company that provides testing infrastructure in Africa, where population growth
has left an increasing number of people without access to necessary healthcare. Connect Afyaʼs vision is toraise the average life expectancy of people in Africa to that of developed countries. Since its establishment
in 2018, Connect Afya has provided essential infrastructure for local diagnostic systems through theoperation of clinical laboratories, medical equipment wholesalers, and clinics in Kenya. It seeks to create asystem to deliver medical care when and where it is needed as a business partner of global healthcare-related
players in Africa. For more information, please visit https://connectafya.com/.

The purpose of this release is to provide our stakeholders with the latest information related to our companies. Although it
may contain information on our products and research and development, it is intended to disclose our management
information and is not intended as promotion, advertisement, or medical advice regarding our products.

For inquiries regarding this press release, please contact:
TAUNS Laboratories, Inc.
Ryosuke Kida, Corporate Planning Oﬃce
TEL: +81-3-6810-9674
E-mail: corporate-planning@tauns.co.jp
Connect Afya Ltd.
Yoichi Shimada, Founder and CEO
E-mail: info@connectafya.com; yoichi.shimada@connectafya.com